EXIM PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
EXIM PHARMA
Largest movements
- Intangible fixed assets +€98,923
up €98,923 (+102.8%), from €96,206 to €195,129
- Stocks and contracts +€25,782
new in 2024: €25,782
- Cash +€19,093
up €19,093 (+190.0%), from €10,049 to €29,142
mainly Debts after one year (+€260,000) and Trade debts (+€6,342)
- Receivables within one year -€4,103
down €4,103 (-65.1%), from €6,305 to €2,202
of which Trade receivables: -€3,088
- Debts after one year +€260,000
up €260,000 (+86.2%), from €301,600 to €561,600
- Profit (loss) carried forward -€131,949
down €131,949 (-48.1%), from -€274,137 to -€406,086
- Trade debts +€6,342
up €6,342 (+17.6%), from €35,982 to €42,324
- Tax, wage and social debts +€4,705
new in 2024: €4,705
of which Remuneration and social security: +€4,577
- Gross operating margin +€39,214
up €39,214 (+37.6%), from -€104,358 to -€65,144
- Staff costs +€10,179
up €10,179 (+18.5%), from €54,969 to €65,148
- Depreciation +€1,236
new in 2024: €1,236
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €113,472 | €252,543 | +€139,071 | +122.6% |
| Fixed assets | 21/28 | €96,206 | €195,129 | +€98,923 | +102.8% |
| Intangible fixed assets | 21 | €96,206 | €195,129 | +€98,923 | +102.8% |
| Current assets | 29/58 | €17,266 | €57,414 | +€40,148 | +232.5% |
| Stocks and contracts in progress | 3 | - | €25,782 | +€25,782 | |
| Stocks | 30/36 | - | €25,782 | +€25,782 | |
| Amounts receivable within one year | 40/41 | €6,305 | €2,202 | -€4,103 | -65.1% |
| Trade receivables | 40 | €3,088 | €0 | -€3,088 | -100.0% |
| Other amounts receivable | 41 | €3,217 | €2,202 | -€1,014 | -31.5% |
| Cash at bank and in hand | 54/58 | €10,049 | €29,142 | +€19,093 | +190.0% |
| Deferred charges and accrued income | 490/1 | €912 | €288 | -€624 | -68.4% |
| Total equity and liabilities | 10/49 | €113,472 | €252,543 | +€139,071 | +122.6% |
| Equity | 10/15 | -€224,137 | -€356,086 | -€131,949 | -58.9% |
| Contributions | 10/11 | €50,000 | €50,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€274,137 | -€406,086 | -€131,949 | -48.1% |
| Amounts payable | 17/49 | €337,608 | €608,629 | +€271,020 | +80.3% |
| Amounts payable after more than one year | 17 | €301,600 | €561,600 | +€260,000 | +86.2% |
| Financial debts | 170/4 | €301,600 | €561,600 | +€260,000 | +86.2% |
| Amounts payable within one year | 42/48 | €36,008 | €47,029 | +€11,020 | +30.6% |
| Trade debts | 44 | €35,982 | €42,324 | +€6,342 | +17.6% |
| Suppliers | 440/4 | €35,982 | €42,324 | +€6,342 | +17.6% |
| Taxes, remuneration and social security | 45 | - | €4,705 | +€4,705 | |
| Taxes | 450/3 | - | €128 | +€128 | |
| Remuneration and social security | 454/9 | - | €4,577 | +€4,577 | |
| Other amounts payable | 47/48 | €26 | €0 | -€26 | -100.0% |
| Remuneration, social security and pensions | 62 | €54,969 | €65,148 | +€10,179 | +18.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | - | €1,236 | +€1,236 | |
| Other operating charges | 640/8 | €548 | €40 | -€508 | -92.7% |
| Gross operating margin | 9900 | -€104,358 | -€65,144 | +€39,214 | +37.6% |
| Operating profit (loss) | 9901 | -€159,874 | -€131,568 | +€28,306 | +17.7% |
| Financial income | 75/76B | €54 | €13 | -€40 | -75.1% |
| Recurring financial income | 75 | €54 | €13 | -€40 | -75.1% |
| Financial charges | 65/66B | €269 | €266 | -€3 | -1.1% |
| Recurring financial charges | 65 | €269 | €266 | -€3 | -1.1% |
| Profit (loss) for the period before taxes | 9903 | -€160,090 | -€131,821 | +€28,269 | +17.7% |
| Income taxes | 67/77 | - | €128 | +€128 | |
| Profit (loss) for the period | 9904 | -€160,090 | -€131,949 | +€28,141 | +17.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€160,090 | -€131,949 | +€28,141 | +17.6% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 7 October 2026 via checked.be.